

1 April 2025

SUPREME COURT PROCEEDINGS AGAINST PROIMMUNE

Holista Colltech Ltd (ASX: HCT) refers to its ASX announcement on 10 March 2025 and to the litigation with The ProImmune Company, LLC ("ProImmune") relating to distribution agreements entered into between HCT and ProImmune, which are detailed in HCT's 2023 annual report.

Late yesterday afternoon, The Honourable Justice Strk of the Supreme Court of Western Australia granted leave for HCT to commence proceedings against Promimmune and its director Albert Crum. HCT's proceedings seek damages, an injunction restraining ProImmune from registering and/or enforcing the judgement ProImmune obtained in the United States ("US Judgment"), interest and costs.

HCT alleges that Crum, on behalf of ProImmune, made various representations including regarding ProImmune's patent RE42,645 E and Immune Formulation 200® product, that those representations were false, and that in reliance of those representations HCT entered into the distribution agreements with ProImmune which resulted in the Judgement. HCT's loss is measured by the US Judgment and legal and other costs HCT has incurred in relation to the distribution agreements.

The late timing of the proceedings delayed preparation of the Company's annual accounts for the year ending 31 December 2024. These accounts will be lodged today.

End of Announcement

This announcement has been approved by the Board of Directors of Holista Colltech Ltd.

ABOUT HOLISTA COLLTECH

Holista Colltech Ltd (**Holista**) is a research-driven biotech company, a result of the merger of Holista Biotech Sdn Bhd and Colltech Australia Ltd. It is listed on the Australian Securities Exchange (**ASX:HCT**), headquartered in Perth and has extensive operations in multiple countries, including Malaysia and North America.

Holista's core business is to conduct research to find natural solutions so that people can live healthier lives. The Group holds proprietary solutions to help food manufacturers produce healthier alternatives – without use of chemicals – that do not compromise tastes and mouthfeel. Building on its partnership network and expertise, Holista has also developed advanced technologies related to collagen and nano-collagen.